Merck executive board member and Merck healthcare CEO Belén Garijo said: "Our collaboration with SFJ illustrates Merck KGaA, Darmstadt, Germany's increasing focus on strategic partnering in order to
This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Vivus CEO John
The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3 novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will
The application seeks approval for KEYTRUDA in combination with pemetrexed (ALIMTA) and platinum chemotherapy (carboplatin or cisplatin) as a first-line treatment for patients with metastatic nonsquamous non-small cell
PHN is the licensor of Gleolan (aminolevulinic acid HCl (ALA)) to NXDC. The companies share an eight-year working relationship. PHN is engaged in the development of drugs that
The companies are partners on a grant titled, "A novel small molecule approach to enhance cancer immunotherapy." Their research plan proposes to develop small-molecule drugs that will stimulate
The recommendation is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New
The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the F508del mutation and one minimal function mutation and is designed to support
Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial
ADCT clinical development senior vice president and chief medical officer Dr Jay Feingold said: "We are very pleased with the efficacy and tolerability achieved with our lead hematological
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.